Form 4: CRISPR Therapeutics Director Simeon George Acquires Over 989,000 Shares

CRISPR Therapeutics AG Director Simeon George, through affiliated investment funds, acquired 989,812 common shares for approximately $51.5 million, increasing his indirect beneficial ownership to over 2 million shares.

Summary

• Simeon George, a Director of CRISPR Therapeutics AG (CRSP), acquired a total of 989,812 common shares through various investment funds.
• The acquisitions occurred on July 16, 2025, at a price of $52.03 per share.
• The total value of the acquired shares is approximately $51.5 million.
• Following these transactions, George Simeon's indirect beneficial ownership in CRISPR Therapeutics AG increased to 2,038,763 common shares.
• The shares were acquired indirectly through SR One Capital Fund II Aggregator, LP, SR One Capital Opportunities Fund I, LP, and AMZL, LP, where George Simeon is the sole managing member of the general partner, SR One Capital Management, LLC.

Sentiment

Score: 8

Explanation: The acquisition of a substantial number of shares by a director, totaling over $51 million, indicates strong insider confidence and a positive outlook for the company's future performance.

Positives

• A significant acquisition of 989,812 common shares by a company director, Simeon George, signals strong insider confidence in CRISPR Therapeutics AG's future prospects.
• The total value of the acquisition, approximately $51.5 million, represents a substantial investment by an insider.
• The increase in indirect beneficial ownership to 2,038,763 shares demonstrates a deepened alignment of interests between the director and shareholders.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider transaction.

Industry Context

Insider buying, particularly of this magnitude, can be seen as a positive signal within the biotechnology and gene editing industry, indicating confidence in the company's pipeline, regulatory progress, or market position. It suggests that a key insider believes the company's stock is undervalued or has significant upside potential.

Comparison to Industry Standards

• Insider purchases of this scale (over $50 million) by a director are generally considered a strong positive signal, often exceeding typical insider transaction sizes seen across various industries.
• Such a substantial investment by a director in a biotechnology firm like CRISPR Therapeutics AG, which operates in the high-risk, high-reward gene editing space, suggests a high degree of conviction in the company's long-term prospects, potentially related to its clinical trial progress or commercialization efforts for therapies like Casgevy.

Related Party Transactions

• The transactions involve indirect beneficial ownership through investment funds (SR One Capital Fund II Aggregator, LP, SR One Capital Opportunities Fund I, LP, and AMZL, LP) where the reporting person, Simeon George, is the sole managing member of the general partner (SR One Capital Management, LLC).
• The reporting person disclaims beneficial ownership for portions where they have no pecuniary interest, which is a standard legal disclaimer for fund managers.

Stakeholder Impact

• Shareholders: The significant insider purchase by a director may instill greater confidence among existing and potential shareholders, signaling management's belief in the company's value and future growth.
• Employees: While not directly impacted, a strong insider signal could indirectly boost employee morale and confidence in the company's stability and prospects.

Key Dates

Recommendation

Keywords

CRISPR Therapeutics AG, CRSP, Insider Trading, Form 4, Share Acquisition, Simeon George, Director, Biotechnology, Gene Editing, SR One Capital